Last deal

$7.5M
Local Amount - GBP 5.7M

Amount

Post-IPO Equity

Stage

28.08.2024

Date

6

all rounds

$26.2M

Total amount

General

About Company
Abingdon Health is an innovative technology-led company that provides rapid and near-patient medical diagnostic testing solutions.

Industry

Sector :

Subsector :

founded date

01.01.2008

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Abingdon Health develops, manufactures and sells products and systems that support the migration of testing from the laboratory closer to the patient, with a focus on hematology oncology. The company uses its expertise in immunodiagnostics, plastic electronics, hardware and software to develop the next generation of testing systems that meet the needs of its customers. Abingdon Health's product portfolio includes ABC-19, an antibody test for Covid-19, as well as tests for self-test HIV, equine infection, human fertility, blood cancer, and more. The company operates in three business segments: Contract Development, Contract Manufacturing, and Product Sales, with key revenue coming from product sales. Abingdon Health is committed to building long-lasting and trusting partnerships with its customers, partners, and colleagues, and its mission is to improve life by making rapid results accessible to all.